BioSpace News Archive

Bio-Path Holdings, Inc. provides an update from several clinical development programs and a 2020 business overview.

BioCardia®, Inc. announced the issuance of three new patents for the company’s technologies in the U.S., China and Japan.

AbbVie announced the creation of a new global business, Allergan Aesthetics, an AbbVie company, and the proposed leadership team for the combined company, effective upon the expected first-quarter 2020 close of the Allergan acquisition.

Event rallying rare disease innovators, investors, and patients, coinciding with J.P. Morgan’s annual healthcare conference

Colospan which develops novel solutions for colorectal surgery, announced today that the United States Food and Drug Administration (FDA) has approved the company’s investigational device exemption (IDE) application.

Entrada Therapeutics, Inc. a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced that it is developing ENTR-501, a novel thymidine phosphorylase enzyme replacement therapy, for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).

Kala Pharmaceuticals, Inc. announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present a corporate overview on Wednesday, January 15, 2020 at 11:30 a.m. PT.

Kronos Bio, Inc., dedicated to the development of first-in-class therapies that modulate historically undruggable targets, announced today that it has appointed Wes Trotter, Ph.D., as Vice President, Chemistry.

ESCAPE Bio, Inc., a clinical stage company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases, announced that Julie Anne Smith, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced the Centers for Medicare and Medicaid Services, which administers the Medicare program, issued its final Clinical Laboratory Fee Schedule for 2020.